Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 8/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454677 | 1.00 | NAAA (0.46) | NAAAFAAHALDH1A1IDH1CSNK2B | |
| SCHEMBL8674159 | 0.90 | NAAA (0.43) | NAAAFAAHALDH1A1IDH1CSNK2B | |
| SCHEMBL8007307 | 0.90 | NAAA (0.43) | NAAAFAAHALDH1A1IDH1CSNK2B | |
| SCHEMBL1750168 | 0.90 | ALDH1A1 (0.55) | NAAAFAAHALDH1A1IDH1CSNK2B | |
| SCHEMBL1750169 | 0.90 | ALDH1A1 (0.55) | NAAAFAAHALDH1A1IDH1CSNK2B | |
| SCHEMBL9970285 | 0.87 | GRM5 (0.46) | NAAAFAAHALDH1A1IDH1 | |
| SCHEMBL3308451 | 0.87 | GRM5 (0.46) | NAAAFAAHALDH1A1IDH1 | |
| SCHEMBL3308447 | 0.87 | GRM5 (0.46) | NAAAFAAHALDH1A1IDH1 | |
| SCHEMBL6442419 | 0.86 | ALDH1A1 (0.46) | NAAAFAAHALDH1A1IDH1CSNK2B | |
| SCHEMBL4327486 | 0.86 | PPARA (0.44) | NAAAFAAHALDH1A1IDH1CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551814-B1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7348349-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1572203-B1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-7109225-B2 | Antidiabetic agents; hypotensive agents; anticholesterol agents; antilipemic agents; antiinflammatory agents; antiproliferative agents | HOFMANN-LA ROCHE INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1392295-B1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-20050267180-A1 | Novel oxazole derivatives | BINGGELI ALFRED | 2005-12-01 | — | — | US | disclosed |
| US-6969725-B2 | Oxazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1572203-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| EP-1551814-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| US-20040157898-A1 | Novel substituted oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-12 | — | — | US | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004041275-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| EP-1392295-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6642389-B2 | For therapy of diabetes | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030055265-A1 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002092084-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267180-A1 | Novel oxazole derivatives | NR1H3, NR1H2, PPARD | NAAA 4646/4885FAAH 3307/4885ALDH1A1 2575/4885 |
| US-20040157898-A1 | Novel substituted oxazole derivatives | OXA1L, SLC5A1, GPR119 | NAAA 3833/4885FAAH 3450/4885ALDH1A1 47/4885 |
| US-20030055265-A1 | Oxazole derivatives | PPARD, PPARA, PPARG | NAAA 3349/4885FAAH 1912/4885ALDH1A1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.